ClinicalTrials.gg
CompletedNCT06933368Updated Oct 26, 2026Results posted

A Clinical Study to Evaluate the Efficacy of a Cetylpyridinium Chloride Mouthwash in Improving Gingival Health and Reducing Plaque Accumulation

An interventional study of Crest Cavity Protection Toothpaste and Experimental Mouthwash in Dental Plaque and Gingivitis, sponsored by HALEON. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by HALEON · Not applicable, Interventional, and Treatment

How we know

Updated Oct 26, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 66 studies in Dental Plaque with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Dental Plaque · United States.

Enrollment
14th of 60
138 · median 80
Started
2025
with 3 others
No phase
34 of 66
7 open now
Registered
52nd of 66
by date
Lead sponsor
4 of 66
HALEON

Among the 66 studies in Dental Plaque with a site in United States, this one is the 14th largest by enrollment of the 60 interventional ones that give a count, is one of 4 that started in 2025, is one of 34 with no phase, and was the 52nd registered.

Dental Plaque

354 studies on the registry are indexed under Dental Plaque; 60 are open to participants now.

Browse Dental Plaque studies →

Open to participants now

8 of the 66 studies in Dental Plaque with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Dental Plaque studies recruiting now, 10 (29%) set no upper age limit and 20 (57%) stop at 75 or younger; 14 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Dental Plaque with a site in United States, or all of them as a file.
02

Study summary

The aim of this 12-week clinical study is to evaluate the ability of an experimental mouthwash, containing 0.085 percent (%) Cetylpyridinium chloride (CPC) as an adjunct to toothbrushing with a regular fluoride toothpaste, to improve gingival health and plaque accumulation compared to a regular fluoride toothpaste alone in participants with plaque-induced mild to moderate gingivitis.

Read the detailed description

This will be a single-center, 12-week, randomized, controlled, single blind (examiner only), 2-treatment arms, parallel group, stratified (by sex [male/female]) study, investigating gingival health and subgingival plaque reduction on healthy participants after twice daily using of an experimental mouthwash containing 0.085% weight/weight (w/w) CPC in combination with a commercially available regular toothpaste containing 0.243% w/w Sodium Fluoride (NaF) compared to a commercially available regular toothpaste containing 0.243% w/w NaF with no known anti-gingivitis nor anti plaque efficacy properties as control group. Approximately 132 participants (approximately 66 per group) will be randomized to ensure approximately 120 evaluable participants (approximately 60 per group) complete the study.

03

Conditions studied

  • Dental Plaque
  • Gingivitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant provision of a signed and dated document indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed.
  • Participant is of either sex and any gender who, at the time of screening, is at least 18 years old, inclusive.
  • A participant who is willing and able to comply with scheduled visits, treatment plan and other study procedures.
  • A participant in good general and mental health with, in the opinion of the investigator or medically qualified designee, no or relevant abnormalities in medical history or upon oral examination, or condition, that would impact the participant's safety, wellbeing or the outcome of the study, if they were to participate in the study, or affect the individual's ability to understand and follow study procedures and requirements.
  • Participant oral health that meets all the following:
  • At screening (visit 1):

    1. Participant with at least 20 natural, permanent teeth.
    2. Participant with at least 40 evaluable surfaces for MGI, bleeding index (BI), and TPI.
    3. A participant with plaque-induced gingivitis, in the opinion of the clinical examiner, as confirmed by a gross visual examination at the screening visit.
  • At baseline (visit 2; prior to dental prophylaxis)

    1. A participant with 10% to 30% bleeding sites.
    2. A participant with overall TPI score >=1.5.

Exclusion criteria

Exclusion Criteria:

  • A participant who is an employee of the site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or a Haleon employee directly involved in the conduct of the study or a member of their immediate family.
  • A participant who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to study entry and/or during study participation.
  • A participant with, in the opinion of the investigator or medically qualified designee, an acute or chronic medical, psychiatric condition or laboratory abnormality or any other clinical serious or unstable conditions (for example, cardiovascular diseases, diabetes, liver disorders, and kidney disorders) that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study.
  • A participant who is a pregnant female (self-reported) or intending to become pregnant over the duration of the study.
  • A female participant who is breastfeeding.
  • A participant with known or suspected intolerance or to the study materials (or closely related compounds) or any of their stated ingredients.
  • A participant unwilling or unable to comply with the Lifestyle Considerations described in this protocol.
  • A participant who is a current smoker or an ex-smoker (including vaping) who stopped within 6 months of Screening.
  • A participant who is using smokeless forms of tobacco (for example, chewing tobacco, gutkha, pan containing tobacco, nicotine-based e-cigarettes).
  • A participant who is diagnosed with xerostomia or is taking any medication that in the view of the investigator is causing xerostomia.
  • A participant who has a medical condition which could have directly influenced gingival bleeding (for example, type 2 diabetes).
  • A participant who has a bleeding disorder that could have affected study outcomes and/or participant safety.
  • A participant who has a recent history (within the last year) of alcohol or other substance abuse.
  • A participant who has a severe oral condition (for example, acute necrotizing ulcerative gingivitis or oral or peri-oral ulceration including herpetic lesions) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant/examiner if they participate in the study.
  • Presence of a tongue or lip piercing, or any other oral feature that could interfere with the usage of a toothbrush.
  • Medication exclusions: At screening (Visit 1):

    1. A participant using any antibiotic medication within 4 weeks prior to screening or at any time during the study.
    2. A participant currently taking an anti-inflammatory medication which, in the opinion of the Investigator, could affect gingival condition.
    3. A participant currently taking a systemic medication (for example, anti-inflammatory, anticoagulant, ) or traditional/ herbal remedy or as a premedication requirement before an invasive examinations and prophylaxis (for example, knee replacement, Mitral valve prolapse etc.), which, in the opinion of the Investigator, could affect plaque/ gingival condition (for example, ibuprofen, aspirin, warfarin, cyclosporin, phenytoin, calcium channel blockers).
    4. A participant who has used an antibacterial dentifrice or mouthwash (for example, chlorhexidine) or any oral care product that in the view of the investigator could interfere with plaque formation or measures of gingivitis, within 4 weeks prior to screening.
  • Medication exclusions: At baseline (Visit 2):

    1. A participant who has taken (in the previous 4 weeks), any antibiotics.
    2. A participant who requires the need for antibiotic premedication prior to a dental prophylaxis or taking some blood thinning medication that prohibit the safe conduct of a dental cleaning. Note: Medical consultation may need to be obtained from participant's physician at the examiner's discretion.
    3. A participant who has taken (in the previous 4 weeks) a systemic medication (for example, anti-inflammatory, anti-coagulant, immunosuppressants) or traditional/ herbal remedy as a premedication requirement before an invasive examinations and prophylaxis (for example, knee replacement, Mitral valve prolapse etc.), which, in the opinion of the Investigator, could affect plaque/ gingival condition (for example, ibuprofen, aspirin, warfarin, cyclosporin, phenytoin, calcium channel blockers).
    4. A participant who has used an antibacterial dentifrice or mouthwash (for example, chlorhexidine) or any oral care product that in the view of the investigator could interfere with plaque formation or measures of gingivitis, in the period between Screening and the Baseline visit.
  • Periodontal exclusions:

    1. A participant who has more than three tooth sites with probing pocket depth >=4 mm.
    2. A participant who is receiving or has received treatment for periodontal disease (including surgery) within 12 months of Screening.
    3. A participant who has gingivitis, which in the opinion of the investigator, is not expected to respond to treatment with an over the counter (OTC) dentifrice.
  • Dental exclusions:

    1. A participant who has active caries that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.
    2. A participant who has dentures (partial or full).
    3. A participant who has an orthodontic appliance (bands, appliances, or fixed/ removable retainers).
    4. A participant who received orthodontic therapy within 3 months of Screening.
    5. A participant who has numerous restorations in a poor state of repair.
    6. A participant who has any dental condition (for example, overcrowding) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.
    7. A participant who has had dental prophylaxis within 12 weeks of Screening.
    8. A participant who has had teeth bleaching within 12 weeks of Screening.
    9. A participant who has high levels of extrinsic stain or calculus deposits, in the opinion of the investigator, that could have interfered with plaque assessments.
  • A participant who has previously been enrolled in this study.
  • A participant who, in the opinion of the investigator or medically qualified designee, should not participate in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
138 participants (actual)

Study arms

  • Experimental
    Test Products (Toothpaste + Mouthwash)

    Participants will be instructed to brush their teeth with the toothpaste (Crest Cavity Protection) for at least one minute twice daily (morning and evening) for 12 weeks. After each brushing, participants will swish 20 milliliter (ml) of experimental mouthwash for 30 seconds without rinsing with water after use of mouthwash.

    Drug: Crest Cavity Protection Toothpaste · Drug: Experimental Mouthwash

  • Active comparator
    Reference Product (Toothpaste)

    Participants will be instructed to brush their teeth with the toothpaste (Crest Cavity Protection) for at least one minute twice daily (morning and evening) for 12 weeks.

    Drug: Crest Cavity Protection Toothpaste

Interventions

  • DrugCrest Cavity Protection Toothpaste

    Toothpaste containing 0.243% w/w NaF.

  • DrugExperimental Mouthwash

    Mouthwash containing 0.085% w/w CPC.

06

What researchers measure

Primary outcomes

  1. Overall Number of Bleeding Sites (NBS) at Week 12 (Test Products Verses [vs.] Reference Product)

    Gingival bleeding was assessed according to the Expanded Bleeding Index (EBI), by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant were probed first (approximately 30 seconds) before recording the number of gingival units that bled. The NBS was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for assessment) with bleeding was observed immediately upon probing or within 30 seconds of probing.

    Time frame: Week 12

Secondary outcomes

  1. Interproximal NBS at Week 12 (Test Products vs. Reference Product)

    Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant were probed first (approximately 30 seconds) before recording the number of gingival units that bled. The NBS was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for assessment) with bleeding was observed immediately upon probing or within 30 seconds of probing.

    Time frame: Week 12

  2. Overall NBS at Week 6 (Test Products vs. Reference Product)

    Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant were probed first (approximately 30 seconds) before recording the number of gingival units that bled. The NBS was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for assessment) with bleeding was observed immediately upon probing or within 30 seconds of probing.

    Time frame: Week 6

  3. Interproximal NBS at Week 6 (Test Products vs. Reference Product)

    Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant were probed first (approximately 30 seconds) before recording the number of gingival units that bled. The NBS was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for assessment) with bleeding was observed immediately upon probing or within 30 seconds of probing.

    Time frame: Week 6

  4. Mean Overall EBI at Week 6 and Week 12 (Test Products vs. Reference Product)

    Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant was probed first (approximately 30 seconds) and gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0 equal to (=) no bleeding after 30 seconds, 1= bleeding observed within 30 seconds of probing, 2= bleeding observed immediately on probing. Lower score indicated improvement in the symptoms.

    Time frame: Week 6 and Week 12

  5. Mean Interproximal EBI at Week 6 and Week 12 (Test Products vs. Reference Product)

    Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant was probed first (approximately 30 seconds) and gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0= no bleeding after 30 seconds, 1= bleeding observed within 30 seconds of probing, 2= bleeding observed immediately on probing. Lower score indicated improvement in the symptoms.

    Time frame: Week 6 and Week 12

  6. Mean Overall Modified Gingival Index (MGI) at Week 6 and Week 12 (Test Products vs. Reference Product)

    The MGI assessment was a non-invasive evaluation which was focused on the visual symptoms of gingivitis (for example, redness, texture, edema). The MGI was assessed for all scorable teeth (second permanent molar to second permanent molar in each arch) by an appropriately qualified examiner using 5-point scoring system ranging from 0 to 4, where 0= Absence of inflammation, 1= Mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit, 2= Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit, 3= Moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit, 4= Severe inflammation; marked redness, edema and/ or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms of gingivitis.

    Time frame: Week 6 and Week 12

  7. Mean Interproximal MGI at Week 6 and Week 12 (Test Products vs. Reference Product)

    The MGI assessment was a non-invasive evaluation which was focused on the visual symptoms of gingivitis (for example, redness, texture, edema). The MGI was assessed for all scorable teeth (second permanent molar to second permanent molar in each arch) by an appropriately qualified examiner using 5-point scoring system ranging from 0 to 4, where 0= Absence of inflammation, 1= Mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit, 2= Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit, 3= Moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit, 4= Severe inflammation; marked redness, edema and/ or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms of gingivitis.

    Time frame: Week 6 and Week 12

  8. Mean Overall Turesky Plaque Index (TPI) at Week 6 and Week 12 (Test Products vs. Reference Product)

    The TPI was used to assess plaque on all gradable teeth. The plaque was disclosed using a plaque disclosing dye solution. TPI was assessed on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites). Disclosed plaque was scored using 6-point scale ranging from 0 to 5, where 0= No plaque, 1= Separate flecks of plaque at the cervical margin, 2= Thin continuous band of plaque (up to 1 millimeter \[mm\]) at the cervical margin, 3= Band of plaque wider than 1 mm but covering less than (\<) 1/3 of the tooth surface, 4= Plaque covering more than or equal to (\>=) 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement.

    Time frame: Week 6 and Week 12

  9. Mean Interproximal TPI at Week 6 and Week 12 (Test Products vs. Reference Product)

    The TPI was used to assess plaque on all gradable teeth. The plaque was disclosed using a plaque disclosing dye solution. TPI was assessed on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites). Disclosed plaque was scored using 6-point scale ranging from 0 to 5, where 0= No plaque, 1= Separate flecks of plaque at the cervical margin, 2= Thin continuous band of plaque (up to 1 mm) at the cervical margin, 3= Band of plaque wider than 1 mm but covering \< 1/3 of the tooth surface, 4= Plaque covering \>= 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement.

    Time frame: Week 6 and Week 12

07

Results

Posted Oct 26, 2026

Participant flow

This study was conducted at a single center in United States of America.

Participant flow — Overall Study
MilestoneTest Products (Toothpaste + Mouthwash)Reference Product (Toothpaste)
Started6868
Completed6566
Not completed32
Withdrew: Did not meet study criteria11
Withdrew: Withdrawal by subject21

Outcome measures

PrimaryOverall Number of Bleeding Sites (NBS) at Week 12 (Test Products Verses [vs.] Reference Product)

Gingival bleeding was assessed according to the Expanded Bleeding Index (EBI), by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant were probed first (approximately 30 seconds) before recording the number of gingival units that bled. The NBS was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for assessment) with bleeding was observed immediately upon probing or within 30 seconds of probing.

Time frame:
Week 12
Reported as:
Least squares mean · bleeding sites
Overall Number of Bleeding Sites (NBS) at Week 12 (Test Products Verses [vs.] Reference Product)
bleeding sitesTest Products (Toothpaste + Mouthwash)Reference Product (Toothpaste)
Overall Number of Bleeding Sites (NBS) at Week 12 (Test Products Verses [vs.] Reference Product)8.9 ± 0.9324.7 ± 0.93
Statistical analysis
  • Test Products (Toothpaste + Mouthwash) vs Reference Product (Toothpaste) · Mixed Model for Repeated Measures · p = <0.0001 · Adjusted mean difference: -15.8 · 95% CI -18.4 to -13.2
SecondaryInterproximal NBS at Week 12 (Test Products vs. Reference Product)

Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant were probed first (approximately 30 seconds) before recording the number of gingival units that bled. The NBS was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for assessment) with bleeding was observed immediately upon probing or within 30 seconds of probing.

Time frame:
Week 12
Reported as:
Least squares mean · bleeding sites
Interproximal NBS at Week 12 (Test Products vs. Reference Product)
bleeding sitesTest Products (Toothpaste + Mouthwash)Reference Product (Toothpaste)
Interproximal NBS at Week 12 (Test Products vs. Reference Product)5.2 ± 0.6816.0 ± 0.67
Statistical analysis
  • Test Products (Toothpaste + Mouthwash) vs Reference Product (Toothpaste) · Mixed Model for Repeated Measures · p = <0.0001 · Adjusted mean difference: -10.8 · 95% CI -12.7 to -8.9
SecondaryOverall NBS at Week 6 (Test Products vs. Reference Product)

Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant were probed first (approximately 30 seconds) before recording the number of gingival units that bled. The NBS was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for assessment) with bleeding was observed immediately upon probing or within 30 seconds of probing.

Time frame:
Week 6
Reported as:
Least squares mean · bleeding sites
Overall NBS at Week 6 (Test Products vs. Reference Product)
bleeding sitesTest Products (Toothpaste + Mouthwash)Reference Product (Toothpaste)
Overall NBS at Week 6 (Test Products vs. Reference Product)9.5 ± 0.7522.4 ± 0.75
Statistical analysis
  • Test Products (Toothpaste + Mouthwash) vs Reference Product (Toothpaste) · Mixed Model for Repeated Measures · p = <0.0001 · Adjusted mean difference: -12.9 · 95% CI -15.0 to -10.8
SecondaryInterproximal NBS at Week 6 (Test Products vs. Reference Product)

Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant were probed first (approximately 30 seconds) before recording the number of gingival units that bled. The NBS was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for assessment) with bleeding was observed immediately upon probing or within 30 seconds of probing.

Time frame:
Week 6
Reported as:
Least squares mean · bleeding sites
Interproximal NBS at Week 6 (Test Products vs. Reference Product)
bleeding sitesTest Products (Toothpaste + Mouthwash)Reference Product (Toothpaste)
Interproximal NBS at Week 6 (Test Products vs. Reference Product)4.8 ± 0.5513.1 ± 0.55
Statistical analysis
  • Test Products (Toothpaste + Mouthwash) vs Reference Product (Toothpaste) · Mixed Model with Repeated Measures · p = <0.0001 · Adjusted mean difference: -8.2 · 95% CI -9.8 to -6.7
SecondaryMean Overall EBI at Week 6 and Week 12 (Test Products vs. Reference Product)

Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant was probed first (approximately 30 seconds) and gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0 equal to (=) no bleeding after 30 seconds, 1= bleeding observed within 30 seconds of probing, 2= bleeding observed immediately on probing. Lower score indicated improvement in the symptoms.

Time frame:
Week 6 and Week 12
Reported as:
Least squares mean · score on a scale
Mean Overall EBI at Week 6 and Week 12 (Test Products vs. Reference Product)
score on a scaleTest Products (Toothpaste + Mouthwash)Reference Product (Toothpaste)
Week 60.09 ± 0.0080.22 ± 0.008
Week 120.08 ± 0.0090.23 ± 0.009
Statistical analysis
  • Test Products (Toothpaste + Mouthwash) vs Reference Product (Toothpaste) · Mixed Model for Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.12 · 95% CI -0.14 to -0.10
  • Test Products (Toothpaste + Mouthwash) vs Reference Product (Toothpaste) · Mixed Model for Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.15 · 95% CI -0.17 to -0.12
SecondaryMean Interproximal EBI at Week 6 and Week 12 (Test Products vs. Reference Product)

Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant was probed first (approximately 30 seconds) and gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0= no bleeding after 30 seconds, 1= bleeding observed within 30 seconds of probing, 2= bleeding observed immediately on probing. Lower score indicated improvement in the symptoms.

Time frame:
Week 6 and Week 12
Reported as:
Least squares mean · score on a scale
Mean Interproximal EBI at Week 6 and Week 12 (Test Products vs. Reference Product)
score on a scaleTest Products (Toothpaste + Mouthwash)Reference Product (Toothpaste)
Week 60.07 ± 0.0080.19 ± 0.008
Week 120.07 ± 0.0100.22 ± 0.010
Statistical analysis
  • Test Products (Toothpaste + Mouthwash) vs Reference Product (Toothpaste) · Mixed Model for Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.11 · 95% CI -0.14 to -0.09
  • Test Products (Toothpaste + Mouthwash) vs Reference Product (Toothpaste) · Mixed Model for Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.15 · 95% CI -0.18 to -0.12
SecondaryMean Overall Modified Gingival Index (MGI) at Week 6 and Week 12 (Test Products vs. Reference Product)

The MGI assessment was a non-invasive evaluation which was focused on the visual symptoms of gingivitis (for example, redness, texture, edema). The MGI was assessed for all scorable teeth (second permanent molar to second permanent molar in each arch) by an appropriately qualified examiner using 5-point scoring system ranging from 0 to 4, where 0= Absence of inflammation, 1= Mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit, 2= Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit, 3= Moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit, 4= Severe inflammation; marked redness, edema and/ or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms of gingivitis.

Time frame:
Week 6 and Week 12
Reported as:
Least squares mean · score on a scale
Mean Overall Modified Gingival Index (MGI) at Week 6 and Week 12 (Test Products vs. Reference Product)
score on a scaleTest Products (Toothpaste + Mouthwash)Reference Product (Toothpaste)
Week 61.13 ± 0.0301.63 ± 0.030
Week 121.18 ± 0.0321.77 ± 0.032
Statistical analysis
  • Test Products (Toothpaste + Mouthwash) vs Reference Product (Toothpaste) · Mixed Model for Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.50 · 95% CI -0.58 to -0.42
  • Test Products (Toothpaste + Mouthwash) vs Reference Product (Toothpaste) · Mixed Model for Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.59 · 95% CI -0.68 to -0.50
SecondaryMean Interproximal MGI at Week 6 and Week 12 (Test Products vs. Reference Product)

The MGI assessment was a non-invasive evaluation which was focused on the visual symptoms of gingivitis (for example, redness, texture, edema). The MGI was assessed for all scorable teeth (second permanent molar to second permanent molar in each arch) by an appropriately qualified examiner using 5-point scoring system ranging from 0 to 4, where 0= Absence of inflammation, 1= Mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit, 2= Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit, 3= Moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit, 4= Severe inflammation; marked redness, edema and/ or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms of gingivitis.

Time frame:
Week 6 and Week 12
Reported as:
Least squares mean · score on a scale
Mean Interproximal MGI at Week 6 and Week 12 (Test Products vs. Reference Product)
score on a scaleTest Products (Toothpaste + Mouthwash)Reference Product (Toothpaste)
Week 61.28 ± 0.0331.79 ± 0.033
Week 121.32 ± 0.0341.93 ± 0.034
Statistical analysis
  • Test Products (Toothpaste + Mouthwash) vs Reference Product (Toothpaste) · Mixed Model for Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.51 · 95% CI -0.60 to -0.42
  • Test Products (Toothpaste + Mouthwash) vs Reference Product (Toothpaste) · Mixed Model for Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.61 · 95% CI -0.70 to -0.51
SecondaryMean Overall Turesky Plaque Index (TPI) at Week 6 and Week 12 (Test Products vs. Reference Product)

The TPI was used to assess plaque on all gradable teeth. The plaque was disclosed using a plaque disclosing dye solution. TPI was assessed on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites). Disclosed plaque was scored using 6-point scale ranging from 0 to 5, where 0= No plaque, 1= Separate flecks of plaque at the cervical margin, 2= Thin continuous band of plaque (up to 1 millimeter \[mm\]) at the cervical margin, 3= Band of plaque wider than 1 mm but covering less than (\<) 1/3 of the tooth surface, 4= Plaque covering more than or equal to (\>=) 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement.

Time frame:
Week 6 and Week 12
Reported as:
Least squares mean · score on a scale
Mean Overall Turesky Plaque Index (TPI) at Week 6 and Week 12 (Test Products vs. Reference Product)
score on a scaleTest Products (Toothpaste + Mouthwash)Reference Product (Toothpaste)
Week 62.83 ± 0.0403.09 ± 0.040
Week 122.67 ± 0.0512.95 ± 0.051
Statistical analysis
  • Test Products (Toothpaste + Mouthwash) vs Reference Product (Toothpaste) · Mixed Model for Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.26 · 95% CI -0.37 to -0.15
  • Test Products (Toothpaste + Mouthwash) vs Reference Product (Toothpaste) · Mixed Model for Repeated Measures · p = 0.0002 · Adjusted mean difference: -0.28 · 95% CI -0.42 to -0.14
SecondaryMean Interproximal TPI at Week 6 and Week 12 (Test Products vs. Reference Product)

The TPI was used to assess plaque on all gradable teeth. The plaque was disclosed using a plaque disclosing dye solution. TPI was assessed on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites). Disclosed plaque was scored using 6-point scale ranging from 0 to 5, where 0= No plaque, 1= Separate flecks of plaque at the cervical margin, 2= Thin continuous band of plaque (up to 1 mm) at the cervical margin, 3= Band of plaque wider than 1 mm but covering \< 1/3 of the tooth surface, 4= Plaque covering \>= 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement.

Time frame:
Week 6 and Week 12
Reported as:
Least squares mean · score on a scale
Mean Interproximal TPI at Week 6 and Week 12 (Test Products vs. Reference Product)
score on a scaleTest Products (Toothpaste + Mouthwash)Reference Product (Toothpaste)
Week 63.08 ± 0.0353.29 ± 0.035
Week 122.92 ± 0.0473.14 ± 0.047
Statistical analysis
  • Test Products (Toothpaste + Mouthwash) vs Reference Product (Toothpaste) · Mixed Model for Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.21 · 95% CI -0.31 to -0.11
  • Test Products (Toothpaste + Mouthwash) vs Reference Product (Toothpaste) · Mixed Model with Repeated Measures · p = 0.0015 · Adjusted mean difference: -0.22 · 95% CI -0.35 to -0.08

Adverse events

Collected over Immediately after completion (signature) of the Informed Consent Form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test Products (Toothpaste + Mouthwash)0/68 (0%)0/68 (0%)8/68 (11.8%)
Reference Product (Toothpaste)0/68 (0%)0/68 (0%)4/68 (5.9%)
Most frequent other events
Most frequent other events
EventTest Products (Toothpaste + Mouthwash)Reference Product (Toothpaste)
Tooth DiscolourationGastrointestinal disorders7/680/68
Aphthous UlcerGastrointestinal disorders0/683/68
Burn Oral CavityInjury, poisoning and procedural complications0/681/68
Skin ExfoliationSkin and subcutaneous tissue disorders1/680/68

Baseline characteristics

The Safety population included all randomized participants who received at least one dose of investigational product.

Age, Continuous
Age, Continuous(years)Test Products (Toothpaste + Mouthwash)Reference Product (Toothpaste)Total
Mean55.2 ± 13.4252.3 ± 14.9053.7 ± 14.21
Sex: Female, Male
Sex: Female, Male(Participants)Test Products (Toothpaste + Mouthwash)Reference Product (Toothpaste)Total
Female383775
Male303161
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Test Products (Toothpaste + Mouthwash)Reference Product (Toothpaste)Total
Hispanic or Latino314
Not Hispanic or Latino6567132
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Test Products (Toothpaste + Mouthwash)Reference Product (Toothpaste)Total
African American/African Heritage5813
Asian - East Asian Heritage022
Asian - South East Asian Heritage011
White - Arabic/North African Heritage011
White - White/Caucasian/European Heritage6356119
08

Study locations

1 site
  • Salus Research Inc
    Fort Wayne, Indiana 46825, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trialregister@haleon.com.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Aug 2025, 3 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

Of 45 industry-sponsored interventional studies with no phase under Dental Plaque, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 3 months is above that.

Counting every sponsor, half of 179 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2025
First posted
Apr 18, 2025
StartActual
Apr 21, 2025
Primary completionActual
Aug 14, 2025
CompletionActual
Aug 14, 2025
Results first posted
Oct 26, 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 26, 2026
Enrollment
136→138
Oct 26, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedOverall Number of Bleeding Sites (OverallNBS) Atat Week 12 (Test Products Verses [vs.] Reference Product)Time frame: Week 12
Oct 26, 2026
Documents
Secondary outcomes
6 edited, 3 added, 3 removed
What changed in the outcomes
  • EditedMean Overall EBI (Overall) Atat Week 6 and Week 12 (Test Products vs. Reference Product)Time frame: Week 6 and Week 12
  • EditedMean Interproximal EBI (Interproximal) Atat Week 6 and Week 12 (Test Products vs. Reference Product)Time frame: Week 6 and Week 12
  • EditedMean Overall Modified Gingival Index (MGI) (Overall) Atat Week 6 and Week 12 (Test Products vs. Reference Product)Time frame: Week 6 and Week 12
  • EditedMean Interproximal MGI (Interproximal) Atat Week 6 and Week 12 (Test Products vs. Reference Product)Time frame: Week 6 and Week 12
  • EditedMean Overall Turesky Plaque Index (TPI) (Overall) at Week 6 and Week 12 (Test Products vs. Reference Product)Time frame: Week 6 and Week 12
  • EditedMean Interproximal TPI (Interproximal) at Week 6 and Week 12 (Test Products vs. Reference Product)Time frame: Week 6 and Week 12
  • AddedInterproximal NBS at Week 12 (Test Products vs. Reference Product)Time frame: Week 12
  • AddedOverall NBS at Week 6 (Test Products vs. Reference Product)Time frame: Week 6
  • AddedInterproximal NBS at Week 6 (Test Products vs. Reference Product)Time frame: Week 6
  • RemovedNumber of Bleeding Sites (Interproximal) At Week 12Time frame: Week 12
  • RemovedNumber of Bleeding Sites (Overall) At Week 6Time frame: Week 6
  • RemovedNumber of Bleeding Sites (Interproximal) At Week 6Time frame: Week 6
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Results posted
    Enrollment 136→138
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedOverall Number of Bleeding Sites (OverallNBS) Atat Week 12 (Test Products Verses [vs.] Reference Product)Time frame: Week 12
    Secondary outcomes 6 edited, 3 added, 3 removed
    What changed in the outcomes
    • EditedMean Overall EBI (Overall) Atat Week 6 and Week 12 (Test Products vs. Reference Product)Time frame: Week 6 and Week 12
    • EditedMean Interproximal EBI (Interproximal) Atat Week 6 and Week 12 (Test Products vs. Reference Product)Time frame: Week 6 and Week 12
    • EditedMean Overall Modified Gingival Index (MGI) (Overall) Atat Week 6 and Week 12 (Test Products vs. Reference Product)Time frame: Week 6 and Week 12
    • EditedMean Interproximal MGI (Interproximal) Atat Week 6 and Week 12 (Test Products vs. Reference Product)Time frame: Week 6 and Week 12
    • EditedMean Overall Turesky Plaque Index (TPI) (Overall) at Week 6 and Week 12 (Test Products vs. Reference Product)Time frame: Week 6 and Week 12
    • EditedMean Interproximal TPI (Interproximal) at Week 6 and Week 12 (Test Products vs. Reference Product)Time frame: Week 6 and Week 12
    • AddedInterproximal NBS at Week 12 (Test Products vs. Reference Product)Time frame: Week 12
    • AddedOverall NBS at Week 6 (Test Products vs. Reference Product)Time frame: Week 6
    • AddedInterproximal NBS at Week 6 (Test Products vs. Reference Product)Time frame: Week 6
    • RemovedNumber of Bleeding Sites (Interproximal) At Week 12Time frame: Week 12
    • RemovedNumber of Bleeding Sites (Overall) At Week 6Time frame: Week 6
    • RemovedNumber of Bleeding Sites (Interproximal) At Week 6Time frame: Week 6
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06933368
Lead sponsor
HALEON
Responsible party
Sponsor
First posted
Apr 18, 2025
Start date
Apr 21, 2025
Primary completion
Aug 14, 2025
Completion
Aug 14, 2025
Results posted
Oct 26, 2026
Last update
Oct 26, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion